Skip to navigation Skip to content

News

Share

Company Says MD1003 (high dose Biotin) Failed to Help Progressive MS in Phase 3 Trial

March 11, 2020

MedDay Pharmaceuticals announced that its second Phase 3 clinical trial of MD1003® (high-dose Biotin) in people with progressive MS failed to meet its primary or secondary endpoints. No adverse safety issues were reported.
  • The trial involved 642 people with primary progressive MS and secondary progressive MS who did not have recent relapses. Participants took MD1003 or placebo three times a day for 15 months.
  • The primary endpoint for the study was reversal of functional disability as measured by the proportion of participants with an improvement in either the standard EDSS scale (that largely tests walking ability), or in the time needed to walk 25 feet, at 12 months and confirmed at 15 months.
  • Biotin is considered a form of vitamin B, and is a component of enzymes in the body that help break down certain substances in the body. It was being tested to see if it could provide support for what may be increased energy demands of brain cells during the course of MS. Biotin is usually obtained from food.
  • The company announced plans to release more detailed results at an upcoming medical meeting.
 Read details about the trial on clinical trials.gov
 
MD1003 is a registered trademark of MedDay Pharmaceuticals
 

About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.

About the National Multiple Sclerosis Society

The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, X, formerly known as Twitter, Instagram, YouTube or 1-800-344-4867.

Share


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.